Somatic variants investigation in critical regulatory pathways

August 25, 2022
This training will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and Human Somatic Mutation Database (HSMD) to identify key somatic variants associated with regulatory genes in ‘omic data and study the genomic characteristics of both target and disease to better understand the clinical relevance. Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, the Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across cancer types.

Attendees will learn how to:

· Use IPA to identify key regulators within a dataset of interest

· Use HSMD to investigate variants for target genes and cancer type of interest

· Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and cancer types

Click here to learn more about HSMD and IPA.

Related videos


Drug repurposing: from large-scale biological data to therapeutics

286 views July 19, 2022

One of the challenges we are facing today is the high cost and slow pace of...


QIAGEN Ingenuity Pathway Analysis (IPA) for grant writing and publications with new features

169 views October 20, 2022

QIAGEN Ingenuity Pathway Analysis (IPA) represents a robust resource to aid...


Multi omics analysis using QIAGEN Ingenuity Pathway Analysis

370 views October 20, 2022

In this 90-minute training session you’ll learn about how QIAGEN Ingenuity...


IPA deeper dive Making most out of user’s core analysis and new features.mp4

242 views October 10, 2022

Many Ingenuity Pathway Analysis (IPA) users have requested a deeper dive...